Studies with Monoclonal Antibodies to Breast Tumors

1985 ◽  
pp. 80-85
Author(s):  
C. F. Lemaistre ◽  
D. P. Edwards ◽  
L. G. Dressler ◽  
B. Lathan ◽  
R. E. Mansel ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Breast Tumors

scholarly journals Immunotherapy and prevention of breast cancer

2020 ◽  
Vol 7 (2) ◽  
pp. 58-70
Author(s):  
Neelam Thacker ◽  
Perianayagam Taneja
Keyword(s):  
Breast Cancer ◽  
Monoclonal Antibodies ◽  
Cancer Patients ◽  
Triple Negative ◽  
Standard Of Care ◽  
Breast Tumors ◽  
Cancer Death ◽  
Breast Cancer Patients ◽  
Conventional Chemotherapy ◽  
Prevention Of Breast Cancer

Breast cancer is the most commonly diagnosed cancer in women and is a leading cause of cancer death in women worldwide. Despite the significant benefit of the use of conventional chemotherapy and monoclonal antibodies in the prognosis of breast cancer patients and although the recent approval of the anti-PD-L1 antibody atezolizumab in combination with chemotherapy has been a milestone for the treatment of patients with metastatic triple-negative breast cancer, immunologic treatment of breast tumors remains a great challenge. In this review, we summarize current breast cancer classification and standard of care, the main obstacles that hinder the success of immunotherapies in breast cancer patients, as well as different approaches that could be useful to enhance the response of breast tumors to immunotherapies.

Keratin polypeptide distribution in benign and malignant breast tumors: subdivision of ductal carcinomas using monoclonal antibodies

1986 ◽  
Vol 51 (1) ◽  
pp. 265-275 ◽  
Author(s):  
Michael Altmannsberger ◽  
Thomas Dirk ◽  
Manfred Droese ◽  
Klaus Weber ◽  
Mary Osborn
Keyword(s):  
Monoclonal Antibodies ◽  
Breast Tumors ◽  
Malignant Breast ◽  
Ductal Carcinomas

scholarly journals Immunotherapy and prevention of breast cancer

2020 ◽  
Vol 7 (2) ◽  
pp. 58-70
Author(s):  
Neelam Thacker ◽  
Perianayagam Taneja
Keyword(s):  
Breast Cancer ◽  
Monoclonal Antibodies ◽  
Cancer Patients ◽  
Triple Negative ◽  
Standard Of Care ◽  
Breast Tumors ◽  
Cancer Death ◽  
Breast Cancer Patients ◽  
Conventional Chemotherapy ◽  
Prevention Of Breast Cancer

Breast cancer is the most commonly diagnosed cancer in women and is a leading cause of cancer death in women worldwide. Despite the significant benefit of the use of conventional chemotherapy and monoclonal antibodies in the prognosis of breast cancer patients and although the recent approval of the anti-PD-L1 antibody atezolizumab in combination with chemotherapy has been a milestone for the treatment of patients with metastatic triple-negative breast cancer, immunologic treatment of breast tumors remains a great challenge. In this review, we summarize current breast cancer classification and standard of care, the main obstacles that hinder the success of immunotherapies in breast cancer patients, as well as different approaches that could be useful to enhance the response of breast tumors to immunotherapies.

scholarly journals Immunotherapy: A Challenge of Breast Cancer Treatment

Cancers ◽  
2019 ◽  
Vol 11 (12) ◽  
pp. 1822 ◽  
Author(s):  
Marilina García-Aranda ◽  
Maximino Redondo
Keyword(s):  
Breast Cancer ◽  
Monoclonal Antibodies ◽  
Cancer Patients ◽  
Triple Negative ◽  
Standard Of Care ◽  
Breast Tumors ◽  
Breast Cancer Treatment ◽  
Cancer Death ◽  
Breast Cancer Patients ◽  
Conventional Chemotherapy

Breast cancer is the most commonly diagnosed cancer in women and is a leading cause of cancer death in women worldwide. Despite the significant benefit of the use of conventional chemotherapy and monoclonal antibodies in the prognosis of breast cancer patients and although the recent approval of the anti-PD-L1 antibody atezolizumab in combination with chemotherapy has been a milestone for the treatment of patients with metastatic triple-negative breast cancer, immunologic treatment of breast tumors remains a great challenge. In this review, we summarize current breast cancer classification and standard of care, the main obstacles that hinder the success of immunotherapies in breast cancer patients, as well as different approaches that could be useful to enhance the response of breast tumors to immunotherapies.

Generation of monoclonal antibodies reactive with nuclear proteins of human primary breast tumors

1988 ◽  
Vol 41 (2) ◽  
pp. 201-205 ◽  
Author(s):  
Bao-Linh Dinh ◽  
Monique Tremblay ◽  
Diane Paradis ◽  
Paul-Emile Roy ◽  
Bernard Tetu
Keyword(s):  
Monoclonal Antibodies ◽  
Breast Tumors ◽  
Nuclear Proteins
Sign in / Sign up

Export Citation Format

Share Document